{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:26:18Z","timestamp":1794500778403,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite standard treatment with systemic corticosteroids and\/or antifungal triazoles, a substantial proportion of patients with allergic bronchopulmonary aspergillosis (ABPA) experience frequent relapses and require long-term treatment despite unfavorable adverse effects. We investigated the efficacy and safety of anti-interleukin (IL)-5\/IL-5 receptor \u03b1 chain (R\u03b1) monoclonal antibodies (mAbs) in patients with ABPA complicated by asthma. ABPA cases treated with anti-IL-5\/IL-5R\u03b1 mAbs were collected from 132 medical institutes in 2018 and published case reports in Japan. Clinical outcomes, laboratory and physiological data, and radiographic findings during 32\u00a0weeks before and after treatment were retrospectively evaluated. We analyzed 29 cases of ABPA: 20 treated with mepolizumab and nine with benralizumab. Treatment with anti-IL-5\/IL-5R\u03b1 mAbs reduced the frequency of exacerbations (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), decreased the dose of oral corticosteroids (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), and improved pulmonary function (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). Mucus plugs in the bronchi shrank or diminished in 18 patients (82%). Despite the clinical\/radiographical improvement, serum levels of total IgE, the key biomarker for the pharmacological response in ABPA, were unchanged. Anti-IL-5\/IL-5R\u03b1 mAbs that directly target eosinophils are promising candidates for the treatment of patients with ABPA, especially those with mucus plugs in the bronchi.\n<\/jats:p>","DOI":"10.1038\/s41598-023-32246-8","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T11:12:19Z","timestamp":1680606739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Katsuyoshi","family":"Tomomatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Yasuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Imokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johsuke","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Tsurikisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuteru","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0832-1939","authenticated-orcid":false,"given":"Mitsuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Oguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"32246_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/cea.12141","volume":"43","author":"R Agarwal","year":"2013","unstructured":"Agarwal, R. et al. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin. Exp. Allergy. 43, 850\u2013873 (2013).","journal-title":"Clin. Exp. Allergy."},{"key":"32246_CR2","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.5415\/apallergy.2018.8.e24","volume":"8","author":"K Asano","year":"2018","unstructured":"Asano, K., Kamei, K. & Hebisawa, A. Allergic bronchopulmonary mycosis\u2014Pathophysiology, histology, diagnosis, and treatment. Asia Pac. Allergy. 8, e24 (2018).","journal-title":"Asia Pac. Allergy."},{"key":"32246_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/13693786.2012.738312","volume":"51","author":"DW Denning","year":"2013","unstructured":"Denning, D. W., Pleuvry, A. & Cole, D. C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med. Mycol. 51, 361\u2013370 (2013).","journal-title":"Med. Mycol."},{"key":"32246_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11046-014-9767-z","volume":"178","author":"R Agarwal","year":"2014","unstructured":"Agarwal, R. Burden and distinctive character of allergic bronchopulmonary aspergillosis in India. Mycopathologia 178, 447\u2013456 (2014).","journal-title":"Mycopathologia"},{"key":"32246_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.7326\/0003-4819-96-3-286","volume":"96","author":"R Patterson","year":"1982","unstructured":"Patterson, R., Greenberger, P. A., Radin, R. C. & Roberts, M. Allergic bronchopulmonary aspergillosis: Staging as an aid to management. Ann Intern Med. 96, 286\u2013291 (1982).","journal-title":"Ann Intern Med."},{"key":"32246_CR6","first-page":"387","volume":"9","author":"MD Ionescu","year":"2014","unstructured":"Ionescu, M. D., Balgradean, M. & Marcu, V. Allergic bronchopulmonary aspergillosis in patient with cystic fibrosis\u2014A case report. Maedica 9, 387\u2013390 (2014).","journal-title":"Maedica"},{"key":"32246_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12890-017-0416-4","volume":"17","author":"E Reece","year":"2017","unstructured":"Reece, E. et al. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: An Irish registry analysis. BMC Pulm. Med. 17, 70 (2017).","journal-title":"BMC Pulm. Med."},{"key":"32246_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2169\/internalmedicine.52.9537","volume":"52","author":"T Ishiguro","year":"2013","unstructured":"Ishiguro, T. et al. Allergic bronchopulmonary aspergillosis with repeated isolation of nontuberculous mycobacteria. Intern. Med. 52, 1721\u20131726 (2013).","journal-title":"Intern. Med."},{"key":"32246_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2169\/internalmedicine.55.5561","volume":"55","author":"T Ishiguro","year":"2016","unstructured":"Ishiguro, T. et al. Pulmonary nontuberculous mycobacteriosis and chronic lower respiratory tract infections in patients with allergic bronchopulmonary mycosis without cystic fibrosis. Intern. Med. 55, 1067\u20131070 (2016).","journal-title":"Intern. Med."},{"key":"32246_CR10","first-page":"100875","volume":"28","author":"H Tsubouchi","year":"2019","unstructured":"Tsubouchi, H. et al. Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection. Respir. Med. Case Rep. 28, 100875 (2019).","journal-title":"Respir. Med. Case Rep."},{"key":"32246_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4103\/ijmr.IJMR_1187_19","volume":"151","author":"R Agarwal","year":"2020","unstructured":"Agarwal, R. et al. Allergic bronchopulmonary aspergillosis. Indian J. Med. Res. 151, 529\u2013549 (2020).","journal-title":"Indian J. Med. Res."},{"key":"32246_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/archinte.1986.00360170130020","volume":"146","author":"R Patterson","year":"1986","unstructured":"Patterson, R., Greenberger, P. A., Halwig, J. M., Liotta, J. L. & Roberts, M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch. Intern. Med. 146, 916\u2013918 (1986).","journal-title":"Arch. Intern. Med."},{"key":"32246_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1378\/chest.130.2.442","volume":"130","author":"R Agarwal","year":"2006","unstructured":"Agarwal, R., Gupta, D., Aggarwal, A. N., Behera, D. & Jindal, S. K. Allergic bronchopulmonary aspergillosis: Lessons from 126 patients attending a chest clinic in north India. Chest 130, 442\u2013448 (2006).","journal-title":"Chest"},{"key":"32246_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","volume":"153","author":"R Agarwal","year":"2018","unstructured":"Agarwal, R. et al. A Randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest 153, 656\u2013664 (2018).","journal-title":"Chest"},{"key":"32246_CR15","doi-asserted-by":"publisher","first-page":"2101787","DOI":"10.1183\/13993003.01787-2021","volume":"59","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur. Respir. J. 59, 2101787 (2022).","journal-title":"Eur. Respir. J."},{"key":"32246_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11046-017-0162-4","volume":"183","author":"A Hamprecht","year":"2018","unstructured":"Hamprecht, A. et al. Azole resistance in Aspergillus fumigatus in patients with cystic fibrosis: A matter of concern?. Mycopathologia 183, 151\u2013160 (2018).","journal-title":"Mycopathologia"},{"key":"32246_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000507216","volume":"181","author":"K Tomomatsu","year":"2020","unstructured":"Tomomatsu, K. et al. Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis complicated by chronic bacterial infection in the airways. Int. Arch. Allergy Immunol. 181, 499\u2013506 (2020).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"32246_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/thx.2010.153312","volume":"66","author":"LA Perez-de-Llano","year":"2011","unstructured":"Perez-de-Llano, L. A. et al. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 66, 539\u2013540 (2011).","journal-title":"Thorax"},{"key":"32246_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jmii.2013.10.003","volume":"49","author":"T Homma","year":"2016","unstructured":"Homma, T., Kurokawa, M., Matsukura, S., Yamaguchi, M. & Adachi, M. Anti-IgE therapy for allergic bronchopulmonary aspergillosis. J. Microbiol. Immunol. Infect. 49, 459\u2013463 (2016).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"32246_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","volume":"3","author":"AL Voskamp","year":"2015","unstructured":"Voskamp, A. L. et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J. Allergy Clin. Immunol. Pract. 3, 192\u2013199 (2015).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"32246_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/02770900902849871","volume":"46","author":"I Randhawa","year":"2009","unstructured":"Randhawa, I., Chin, T. & Nussbaum, E. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: A novel approach. J. Asthma 46, 445\u2013447 (2009).","journal-title":"J. Asthma"},{"key":"32246_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3109\/02770903.2010.491144","volume":"47","author":"RY Lin","year":"2010","unstructured":"Lin, R. Y., Sethi, S. & Bhargave, G. A. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J. Asthma 47, 942\u2013945 (2010).","journal-title":"J. Asthma"},{"key":"32246_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jaip.2015.11.014","volume":"4","author":"JM Kelso","year":"2016","unstructured":"Kelso, J. M. Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab. J. Allergy Clin. Immunol. Pract. 4, 364\u2013365 (2016).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"32246_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12325-022-02307-x","volume":"40","author":"H Koike","year":"2023","unstructured":"Koike, H. et al. A review of Anti-IL-5 therapies for eosinophilic granulomatosis with polyangiitis. Adv Ther. 40, 25\u201340 (2023).","journal-title":"Adv Ther."},{"key":"32246_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.alit.2022.10.004","volume":"72","author":"K Asano","year":"2023","unstructured":"Asano, K., Suzuki, Y., Tanaka, J., Kobayashi, K. & Kamide, Y. Treatments of refractory eosinophilic lung diseases with biologics. Allergol Int. 72, 31\u201340 (2023).","journal-title":"Allergol Int."},{"key":"32246_CR26","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","volume":"8","author":"F Schleich","year":"2020","unstructured":"Schleich, F. et al. Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature. J. Allergy Clin. Immunol. Pract. 8, 2412\u20132413 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"32246_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12890-018-0617-5","volume":"18","author":"T Terashima","year":"2018","unstructured":"Terashima, T., Shinozaki, T., Iwami, E., Nakajima, T. & Matsuzaki, T. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. BMC Pulm. Med. 18, 53 (2018).","journal-title":"BMC Pulm. Med."},{"key":"32246_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.alit.2018.03.004","volume":"67","author":"N Oda","year":"2018","unstructured":"Oda, N. et al. Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. Allergol. Int. 67, 521\u2013523 (2018).","journal-title":"Allergol. Int."},{"key":"32246_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","volume":"68","author":"S Soeda","year":"2019","unstructured":"Soeda, S. et al. Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab. Allergol. Int. 68, 377\u2013379 (2019).","journal-title":"Allergol. Int."},{"key":"32246_CR30","volume":"32","author":"K Tsubouchi","year":"2021","unstructured":"Tsubouchi, K. et al. A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab. Respir. Med. Case Rep. 32, 101339 (2021).","journal-title":"Respir. Med. Case Rep."},{"key":"32246_CR31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2169\/internalmedicine.6217-20","volume":"60","author":"H Matsuura","year":"2021","unstructured":"Matsuura, H. et al. Successful treatment with benralizumab for allergic bronchopulmonary aspergillosis that developed after disastrous heavy rainfall in Western Japan. Intern. Med. 60, 1443\u20131450 (2021).","journal-title":"Intern. Med."},{"key":"32246_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/medicina58010053","volume":"58","author":"A O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly, A. & Dunican, E. The use of targeted monoclonal antibodies in the treatment of ABPA-A case series. Medicina 58, 53 (2021).","journal-title":"Medicina"},{"key":"32246_CR33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck, R. et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 125, 1344\u20131353 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32246_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","volume":"69","author":"K Tomomatsu","year":"2020","unstructured":"Tomomatsu, K. et al. Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment. Allergol. Int. 69, 636\u2013638 (2020).","journal-title":"Allergol. Int."},{"key":"32246_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/JAA.S270298","volume":"13","author":"N Drick","year":"2020","unstructured":"Drick, N. et al. Switch from IL-5 to IL-5-receptor alpha antibody treatment in severe eosinophilic asthma. J. Asthma Allergy. 13, 605\u2013614 (2020).","journal-title":"J. Asthma Allergy."},{"key":"32246_CR36","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/all.14693","volume":"76","author":"JE Kavanagh","year":"2020","unstructured":"Kavanagh, J. E. et al. Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma. Allergy 76, 1890\u20131893 (2020).","journal-title":"Allergy"},{"key":"32246_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.rmed.2009.09.005","volume":"104","author":"R Agarwal","year":"2010","unstructured":"Agarwal, R. et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir. Med. 104, 204\u2013210 (2010).","journal-title":"Respir. Med."},{"key":"32246_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/myc.12423","volume":"59","author":"R Agarwal","year":"2016","unstructured":"Agarwal, R. et al. Utility of IgE (total and Aspergillus fumigatus-specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis. Mycoses 59, 1\u20136 (2016).","journal-title":"Mycoses"},{"key":"32246_CR39","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jaci.2020.08.029","volume":"147","author":"K Asano","year":"2021","unstructured":"Asano, K. et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation. J. Allergy Clin. Immunol. 147, 1261\u20131268 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32246_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1378\/chest.07-0808","volume":"132","author":"R Agarwal","year":"2007","unstructured":"Agarwal, R. et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: An analysis of 155 patients. Chest 132, 1183\u20131190 (2007).","journal-title":"Chest"},{"key":"32246_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican, E. M. et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J. Clin. Invest. 128, 997\u20131009 (2018).","journal-title":"J. Clin. Invest."},{"key":"32246_CR42","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.3389\/fimmu.2018.02346","volume":"9","author":"S Ueki","year":"2018","unstructured":"Ueki, S., Hebisawa, A., Kitani, M., Asano, K. & Neves, J. S. Allergic bronchopulmonary aspergillosis\u2014A luminal hypereosinophilic disease with extracellular trap cell death. Front. Immunol. 9, 2346 (2018).","journal-title":"Front. Immunol."},{"key":"32246_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaci.2015.04.041","volume":"137","author":"S Ueki","year":"2016","unstructured":"Ueki, S. et al. Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. J. Allergy Clin. Immunol. 137, 258\u2013267 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32246_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973\u2013984 (2009).","journal-title":"N. Engl. J. Med."},{"key":"32246_CR45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette, M. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 132, 1086\u20131096 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32246_CR46","doi-asserted-by":"publisher","first-page":"e12081","DOI":"10.1002\/clt2.12081","volume":"11","author":"T van der Veer","year":"2021","unstructured":"van der Veer, T. et al. Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab. Clin. Transl. Allergy 11, e12081 (2021).","journal-title":"Clin. Transl. Allergy"},{"key":"32246_CR47","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.12998\/wjcc.v9.i23.6922","volume":"9","author":"T Nishimura","year":"2021","unstructured":"Nishimura, T. et al. Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report. World J. Clin. Cases 9, 6922\u20136928 (2021).","journal-title":"World J. Clin. Cases"},{"key":"32246_CR48","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2169\/internalmedicine.6679-20","volume":"60","author":"S Mikura","year":"2021","unstructured":"Mikura, S. et al. Successful treatment of mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab. Intern. Med. 60, 2839\u20132842 (2021).","journal-title":"Intern. Med."},{"key":"32246_CR49","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","volume":"8","author":"RP Ramonell","year":"2020","unstructured":"Ramonell, R. P., Lee, F. E., Swenson, C. & Kuruvilla, M. Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series. J. Allergy Clin. Immunol. Pract. 8, 742\u2013743 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"32246_CR50","first-page":"101723","volume":"39","author":"Y Kai","year":"2022","unstructured":"Kai, Y. et al. Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report. Respir. Med. Case Rep. 39, 101723 (2022).","journal-title":"Respir. Med. Case Rep."},{"key":"32246_CR51","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson, E. L. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med. 375, 2335\u20132348 (2016).","journal-title":"N. Engl. J. Med."},{"key":"32246_CR52","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg, A. et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: Results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br. J. Dermatol. 182, 1120\u20131135 (2020).","journal-title":"Br. J. Dermatol."},{"key":"32246_CR53","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378, 2486\u20132496 (2018).","journal-title":"N. Engl. J. Med."},{"key":"32246_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler, M. E. et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): An open-label extension study. Lancet Respir. Med. 10, 11\u201325 (2022).","journal-title":"Lancet Respir. Med."},{"key":"32246_CR55","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert, C. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394, 1638\u20131650 (2019).","journal-title":"Lancet"},{"key":"32246_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jaip.2021.11.029","volume":"10","author":"M Frohlich","year":"2022","unstructured":"Frohlich, M., Olivenstein, R. & Cormier, M. Eosinophilic pulmonary complications of dupilumab in 2 patients with asthma and chronic rhinosinusitis with nasal polyps. J. Allergy Clin. Immunol. Pract. 10, 617\u2013619 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"32246_CR57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacig.2022.03.006","volume":"1","author":"K Yamazaki","year":"2022","unstructured":"Yamazaki, K. et al. Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab. J. Allergy Clin. Immunol. Glob. 1, 180\u2013182 (2022).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"32246_CR58","first-page":"260","volume":"58","author":"V Muthu","year":"2020","unstructured":"Muthu, V. et al. Allergic bronchopulmonary aspergillosis (ABPA) sans asthma: A distinct subset of ABPA with a lesser risk of exacerbation. Med. Mycol. 58, 260\u2013263 (2020).","journal-title":"Med. Mycol."},{"key":"32246_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.alit.2017.04.011","volume":"67","author":"T Oguma","year":"2018","unstructured":"Oguma, T. et al. Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. Allergol. Int. 67, 79\u201384 (2018).","journal-title":"Allergol. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32246-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32246-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32246-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T11:30:59Z","timestamp":1680607859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32246-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32246"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32246-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KA received lecture fees from GlaxoSmithKline plc and AstraZeneca K.K., Novartis, Sanofi. KT received lecture fees from AstraZeneca K.K. NH received personal fees from AstraZeneca K.K, GlaxoSmithKline plc, Novartis, Sanofi and grants from AstraZeneca K.K.\u00a0JT received a research grant from GlaxoSmithKline plc. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5468"}}